These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30712401)

  • 1. Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity.
    Marinho AT; Miranda JP; Caixas U; Charneira C; Gonçalves-Dias C; Marques MM; Monteiro EC; Antunes AMM; Pereira SA
    Drug Metab Rev; 2019 Feb; 51(1):76-90. PubMed ID: 30712401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Reactive Metabolites of Nevirapine Require Distinct Glutathione S-Transferase Isoforms for Bioinactivation.
    Dekker SJ; Zhang Y; Vos JC; Vermeulen NP; Commandeur JN
    Chem Res Toxicol; 2016 Dec; 29(12):2136-2144. PubMed ID: 27989146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nevirapine bioactivation and covalent binding in the skin.
    Sharma AM; Klarskov K; Uetrecht J
    Chem Res Toxicol; 2013 Mar; 26(3):410-21. PubMed ID: 23387501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine--a possible factor in nevirapine toxicity.
    Antunes AM; Godinho AL; Martins IL; Justino GC; Beland FA; Marques MM
    Chem Res Toxicol; 2010 May; 23(5):888-99. PubMed ID: 20392079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine.
    Antunes AM; Duarte MP; Santos PP; Gamboa da Costa G; Heinze TM; Beland FA; Marques MM
    Chem Res Toxicol; 2008 Jul; 21(7):1443-56. PubMed ID: 18597499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent Histone Modification by an Electrophilic Derivative of the Anti-HIV Drug Nevirapine.
    Harjivan SG; Charneira C; Martins IL; Pereira SA; Espadas G; Sabidó E; Beland FA; Marques MM; Antunes AMM
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33802579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries.
    Srivastava A; Lian LY; Maggs JL; Chaponda M; Pirmohamed M; Williams DP; Park BK
    Drug Metab Dispos; 2010 Jan; 38(1):122-32. PubMed ID: 19797610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in hepatic and intestinal contributions to nevirapine biotransformation in rats.
    Pinheiro PF; Marinho AT; Antunes AM; Marques MM; Pereira SA; Miranda JP
    Chem Biol Interact; 2015 May; 233():115-21. PubMed ID: 25818046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein adducts as prospective biomarkers of nevirapine toxicity.
    Antunes AM; Godinho AL; Martins IL; Oliveira MC; Gomes RA; Coelho AV; Beland FA; Marques MM
    Chem Res Toxicol; 2010 Nov; 23(11):1714-25. PubMed ID: 20809596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of nevirapine analogs to study the metabolic activation of nevirapine.
    Tateishi Y; Ohe T; Yasuda D; Takahashi K; Nakamura S; Kazuki Y; Mashino T
    Drug Metab Pharmacokinet; 2020 Apr; 35(2):238-243. PubMed ID: 32184040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte spheroids as a competent in vitro system for drug biotransformation studies: nevirapine as a bioactivation case study.
    Pinheiro PF; Pereira SA; Harjivan SG; Martins IL; Marinho AT; Cipriano M; Jacob CC; Oliveira NG; Castro MF; Marques MM; Antunes AMM; Miranda JP
    Arch Toxicol; 2017 Mar; 91(3):1199-1211. PubMed ID: 27417440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine.
    Antunes AM; Novais DA; da Silva JL; Santos PP; Oliveira MC; Beland FA; Marques MM
    Org Biomol Chem; 2011 Oct; 9(22):7822-35. PubMed ID: 21969039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2'-Deoxythymidine adducts from the anti-HIV drug nevirapine.
    Antunes AM; Wolf B; Oliveira MC; Beland FA; Marques MM
    Molecules; 2013 Apr; 18(5):4955-71. PubMed ID: 23624649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash.
    Sharma AM; Novalen M; Tanino T; Uetrecht JP
    Chem Res Toxicol; 2013 May; 26(5):817-27. PubMed ID: 23590230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients.
    Meng X; Howarth A; Earnshaw CJ; Jenkins RE; French NS; Back DJ; Naisbitt DJ; Park BK
    Chem Res Toxicol; 2013 Apr; 26(4):575-83. PubMed ID: 23448204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity.
    Caixas U; Antunes AM; Marinho AT; Godinho AL; Grilo NM; Marques MM; Oliveira MC; Branco T; Monteiro EC; Pereira SA
    Toxicology; 2012 Nov; 301(1-3):33-9. PubMed ID: 22750752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-dependent metabolism of nevirapine in rats: impact on plasma levels, pharmacokinetics and interaction with nortriptyline.
    Usach I; Compañ P; Peris JE
    Int J Antimicrob Agents; 2018 May; 51(5):707-713. PubMed ID: 29309900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of danger signals in nevirapine-induced skin rash.
    Zhang X; Sharma AM; Uetrecht J
    Chem Res Toxicol; 2013 Sep; 26(9):1378-83. PubMed ID: 23947594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
    Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
    HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.